Clinical Trials Logo

Clinical Trial Summary

This study will compare serotonin transporter proteins in people with alcoholism and healthy volunteers to examine how these proteins may be related to the inability of people with alcoholism to appropriately regulate their alcohol consumption. Serotonin transporters regulate levels of the brain chemical serotonin. Problems in this regulation have been implicated in alcoholism.

Healthy normal volunteers and people who suffer from alcoholism who are between 18 and 75 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, psychiatric diagnostic interview, blood and urine tests, an electrocardiogram, urine toxicology screen, and written psychological evaluations.

Participants undergo positron emission tomography (PET) and magnetic resonance imaging (MRI) scanning to measure serotonin transporter levels in the brain.

PET uses small amounts of a radioactive chemical called a tracer that "labels" the serotonin transporters in the brain. The tracer used in this study is [11C]DASB. For the procedure, the subject lies on the scanner bed. A special mask is fitted to the head and attached to the bed to help keep the subject's head still during the scan so the images will be clear. A brief scan is done just before the radioactive tracer is injected. This scan provides measures of the brain that will help in the precise calculation of information from subsequent scans. After the tracer is injected through a catheter (plastic tube) placed in the arm, pictures are taken for about 2 hours.

MRI uses a magnetic field and radio waves to produce pictures of brain structure. The subject lies on a bed that slides into the tube-like scanner, wearing earplugs to muffle loud noises the machine makes when the magnetic fields are switched. The scan takes about an hour, during which time the subject can communicate with the technician.


Clinical Trial Description

Alcoholism is characterized by the inability of individuals to regulate their consumption of alcohol appropriately. Serotonergic dysfunction has been implicated in the pathophysiology of this illness. Serotonin transporters (SERT) critically regulate the tone of serotonergic transmission (Gobbi et al 2001). In a brain imaging study using the SPECT radioligand, [123I] Beta-CIT, male alcoholics who had abstained from alcohol for more than four weeks, had significantly reduced serotonin transporters in the raphe area of the brainstem compared to healthy control subjects (Heinz et al 1998). However, the [123I] Beta-CIT ligand, binds with high affinity to both the dopamine transporter (DAT) and SERT. Binding of [123I] Beta-CIT in regions rich in SERT or DAT have been attributed to SERT and DAT respectively but in regions of mixed innervation (e.g. cortical regions), it is not possible to distinguish between SERT and DAT.

[11C]DASB is a PET ligand with high affinity for SERT with almost 1,000 fold selectivity versus DAT. Using this tracer, we will be able to measure SERT binding in cortical and subcortical brain regions including those with mixed innervation. [11C] DASB PET studies in humans (Houle et al 2000; Meyer et al 2001) indicate the feasibility of quantifying SERT binding in SERT rich regions. In the current protocol, we plan to use PET imaging with the radioligand, [11C] DASB, for serotonin transporter (SERT) to delineate regional abnormalities in SERT binding in two subject groups consisting of 30 patients with alcoholism and 30 healthy volunteers. Our goal of the present study is to further our understanding of the roles of the serotonergic systems in the pathophysiology of alcoholism. ;


Study Design

N/A


Related Conditions & MeSH terms


NCT number NCT00085865
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase N/A
Start date June 2004
Completion date July 2006

See also
  Status Clinical Trial Phase
Recruiting NCT05054738 - CRP and S&A for Inpatient Veterans N/A
Completed NCT02233738 - Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services N/A
Completed NCT05877807 - Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
Completed NCT00000437 - Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Phase 4
Completed NCT00536146 - The Stress-Hormone System in Alcohol-Dependent Subjects N/A
Terminated NCT00890149 - Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults Phase 2
Completed NCT02939352 - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues Early Phase 1
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Completed NCT01553136 - Varenicline Treatment of Alcohol Dependence in Smokers Phase 2
Completed NCT01389297 - Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery N/A
Completed NCT01760785 - Valproate for Mood Swings and Alcohol Use Following Head Injury N/A
Completed NCT01113164 - Matching Genotypes and Serotonergic Medications for Alcoholism Phase 1
Completed NCT00768508 - Combined Pharmacotherapies for Alcoholism Phase 3
Completed NCT00127231 - Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women N/A
Terminated NCT02842528 - Cognitive Vulnerability Factors in Alcohol-dependence N/A
Completed NCT00367575 - An Internet-based Intervention for Problem Drinking N/A
Completed NCT00223639 - New Medications to Treat Alcohol Dependence Phase 2
Completed NCT00583440 - 12-step Facilitation for the Dually Diagnosed Phase 1/Phase 2
Completed NCT00167687 - Prazosin Alcohol Dependence IVR Study Phase 4